Showing 1 - 10 of 16
Trials that intend to conduct an economic analysis are less likely to report economic data than effectiveness data. Where economic results do appear, they are published later, and in journals with lower impact factors. These results suggest that economic output may be more susceptible than...
Persistent link: https://www.econbiz.de/10011001490
Persistent link: https://www.econbiz.de/10005404997
Cost estimates for the drug of interest, its comparator and concomitant drugs are an important component of pharmacoeconomic evaluations. However, whilst in general considerable efforts are made by analysts to ensure valid and accurate parameter inputs, the methods for estimating drug costs are...
Persistent link: https://www.econbiz.de/10010848939
A willingness to trade the cost effectiveness and QALY gains against other factors indicates that economic efficiency and QALY maximisation are not the only considerations of committee members when making recommendations on the use of medicines in Wales. On average, appraisal committee...
Persistent link: https://www.econbiz.de/10011001587
<Emphasis Type="Bold">Background: There have been several explorations of factors influencing the reimbursement decisions of the National Institute for Health and Clinical Excellence (NICE) but not of other UK-based health technology assessment (HTA) organizations. <Emphasis Type="Bold">Objective: This study aimed to explore the factors...</emphasis></emphasis>
Persistent link: https://www.econbiz.de/10011001744
Non-compliance with prescribed regimens poses a significant problem in clinical therapeutics - patients who do not take their medications according to the labelling instructions are at higher risk of treatment failure, and this may have adverse effects on health outcome and healthcare costs....
Persistent link: https://www.econbiz.de/10005449157
Persistent link: https://www.econbiz.de/10005449171
Persistent link: https://www.econbiz.de/10010634530
Persistent link: https://www.econbiz.de/10010848957
When going 'beyond the patient', to measure QALYs for unpaid carers, a number of additional methodological considerations and value judgements must be made. While there is no theoretical reason to restrict the measurement of QALYs to patients, decisions have to be made about which carers to...
Persistent link: https://www.econbiz.de/10010614320